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Abstract
Introduction: The mechanism by which weakness develops in idiopathic inflamma-
tory myopathies (IIMs) is still unclear. In this study we investigated the maximum
force of single muscle fibers from patients with IIMs.
Methods: Permeabilized single muscle fibers from patients with IIMs and healthy
controls were subjected to contractility measurements. Maximum force and specific
force production (maximum force normalized to fiber size) and fiber type were deter-
mined for each isolated fiber.
Results: A total of 178 fibers were studied from five patients with IIMs and 95 fibers
from four controls. Specific force production was significantly lower in the IIM group
for all fiber types.
Discussion: The findings from this exploratory study suggest that weakness in IIMs
may, in part, be caused by dysfunction of the contractile apparatus. These findings
provide a basis for further studies into the mechanisms underlying weakness in IIMs.
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1 | INTRODUCTION
Idiopathic inflammatory myopathies (IIMs) are autoimmune muscle
disorders of unknown cause that include dermatomyositis (DM), poly-
myositis (PM), necrotizing autoimmune myopathy (NAM), and
inclusion-body myositis (IBM). In contrast to many hereditary myopa-
thies, where abnormal or dysfunctional proteins may lead to impaired
muscle fiber contractility,1–3 the mechanism of weakness in IIMs is
less clear. Weakness is unlikely to be due solely to the loss of fibers
from inflammatory necrosis, as the degree of inflammation and muscle
weakness do not correlate,4 the number of necrotic fibers from histo-
logical analysis is usually small,5–8 and typically a rapid improvement
in strength follows treatment with corticosteroids.6,7 Theoretically,
weakness results from either a decrease in fiber numbers or impaired
contractile function of individual fibers. We hypothesized that inflam-
mation leads to impaired contractile function, and employed in vitro
permeabilized single-muscle-fiber contractility studies to assess con-
tractile function at a cellular level in IIM patients and healthy controls.
2 | METHODS
2.1 | Muscle biopsies
Adult participants with suspected IIM and who were immunosuppres-
sive treatment-naive were recruited at Tygerberg Academic Hospital,
Cape Town, South Africa, and referred to undergo diagnostic muscle
biopsies. Only tissue from participants with a confirmed diagnosis of
IIM, based on accepted criteria,9,10 and who had responded to cortico-
steroid treatment (initiated after the muscle biopsy) at 6 weeks after
initiation, was included in the study. Patients with IBM were excluded,
due to the different pathogenesis, course, time to diagnosis, and
Abbreviations: CSA, cross-sectional area; DM, dermatomyositis; IBM, inclusion-body
myositis; IIM, idiopathic inflammatory myopathy; MRC, Medical Research Council; NAM,
necrotizing autoimmune myopathy; P0, maximum force; PM, polymyositis; SF, specific force;
TNF-α, tumor necrosis factor-alpha.
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response to treatment.11–13 Controls consisted of healthy adults who
donated muscle samples for research at the University of Cape Town
Research Unit for Exercise Science and Sports Medicine. The human
research ethics committees of both Stellenbosch University and the
University of Cape Town approved the study and participants pro-
vided informed consent.
Muscle biopsies were performed under local anesthesia and were
taken from the vastus lateralis muscle, 2 to 3 cm anterior to the mid-
point of a line connecting the greater trochanter and the superior
patellar margin. In controls, biopsies were performed using a
Bergström needle via a 5- to 7-mm incision. In patients with IIM, open
biopsies were performed to ensure acquisition of sufficient tissue for
diagnostic purposes, and small segments of muscle were allocated to
this study. Fresh muscle specimens were divided into two or three
samples of approximately 6 × 4 × 4 mm, rapidly frozen in liquid nitro-
gen, and stored at −200C until analysis. Before analysis, each stored
sample was thawed briefly in phosphate-buffered saline at 37C for
1 minute and divided into smaller bundles, each consisting of 20 to
40 fibers. These bundles were then submerged into skinning solution
containing 50% glycerol (pH 7.00) and stored at 4C for 24 hours, rep-
laced with fresh skinning solution the following day, and then stored
at −20C until analysis.14
2.2 | Contractility studies
Contractile properties of skinned single fibers were analyzed as previ-
ously described using a permeabilized single-fiber test system (Aurora
Scientific, Ontario, Canada).15 Cross-sectional area (CSA) was deter-
mined from the diameter of the fiber using the equation π [(0.8 × fiber
diameter) / 2]2, where 0.8 is to correct for an estimated 20% fiber swell-
ing.16 Absolute force was measured in milli-newtons, and specific force
(SF) was calculated as maximum force (P0) normalized to CSA and
expressed as kilo-newtons per meter squared. All experiments were per-
formed at 12C. The myosin heavy chain composition of each fiber was
individually determined with gel electrophoresis and silver staining.17
2.3 | Statistical analysis
Statistical comparisons between IIMs and controls were performed
for all fiber types combined (types I, IIA, IIX, and hybrid), and for type I
and IIA fibers separately. Type IIX and hybrid fibers were not com-
pared separately due to their absence or small numbers in the biop-
sies. The D'Agostino-Pearson normality test was used to test for
normality of distribution. The unpaired t test with Welch's correction
was used to compare means and medians when data sets displayed a
normal distribution, whereas the nonparametric Mann–Whitney
U test was used for data sets with non–normally distributed data.
Statistical analysis was performed using GraphPad Prism version
7 (GraphPad Software, La Jolla, California). For all parameters, mean
± standard deviation (SD) and median with interquartile range were
calculated. Statistical significance was set at P < .05.
3 | RESULTS
Participants included consisted of four healthy controls (all females;
mean age, 28 years) and five patients with IIMs (all females; mean age,
48 years). The median knee extension Medical Research Council
(MRC) strength score for the IIM group was 4 (Table 1). Select muscle
histology images are shown in Figure S1 online.
3.1 | CSA, P0, and SF
Overall, 178 fibers were studied from patients with IIMs, amounting to
55 type I, 98 type IIA, 6 type IIX, and 19 hybrid fibers (13 I/IIA, 2 I/IIX,
4 IIA/IIX). A total of 95 fibers, consisting of 59 type I, 29 type IIA, and
7 hybrid fibers (all I/IIA), were studied from the healthy control group.
Combined, there was no difference in mean CSA between the IIM
and control groups. When compared separately, mean type I fiber
CSA was 9% smaller in the IIMs group compared with controls,
whereas mean type IIA fiber CSA was 24% smaller in the control
TABLE 1 Demographic and clinical characteristics of participantsa
Participant Diagnosis Age (years)




IIM1 DM 42 5 3
IIM2 PM 60 4 4
IIM3 DM 58 4 3
IIM4 NAM 26 4 1
IIM5 NAM 53 4− 4
HC1 HC 22 Not tested 0
HC2 HC 44 Not tested 0
HC3 HC 27 Not tested 0
HC4 HC 20 Not tested 0
Abbreviations: DM, dermatomyositis; HC, healthy control; IIM, idiopathic inflammatory myopathy; MRC, Medical Research Council; NAM, necrotizing
autoimmune myopathy; PM, polymyositis.
aAll females.
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group (Table 2). Combined, P0 and SF were 15% and 30% lower in the
IIMs group, respectively. P0 and SF of type I fibers were 42% and 30%
lower in the IIMs group, whereas P0 and SF of type IIA fibers were
16% and 35% lower (Figure 1 and Table 2).
4 | DISCUSSION
The findings of this study suggest that contractile force is impaired in
IIMs, which is independent of a decrease in fiber size, as evidenced by
decreased SF after correcting for CSA. The implication of this finding
is that muscle weakness in IIMs is related to a functional impairment
of muscle fiber contraction, and not a decrease in fiber size.
A number of different mechanisms have been proposed to explain
weakness and fatigue in IIMs, including impaired sarcoplasmic reticulum
Ca2+ release18 and abnormalities in energy metabolism, such as adeno-
sine monophosphate deaminase 1 (AMPD1) deficiency.4 However, we
also observed impaired contractility, although Ca2+ and adenosine tri-
phosphate were provided in sufficient quantities by the activating solu-
tion, thus discrediting abnormal Ca2+ release and energy metabolism.
A possible explanation for the impaired contractility may involve
an interaction between one or more components of the inflammatory
response and the contractile apparatus or its supporting structures.
One such component is tumor necrosis factor-alpha (TNF-α), which
has been shown to decrease contractile force of skeletal muscles in
animal models.19–22 in vivo and in vitro experiments utilizing dog,
hamster, and mouse models have shown impaired contractility within
hours after TNF-α administration or incubation, both at the muscle
(diaphragm) and myofibrillar level. The effect of TNF-α was partially
blocked by the cyclooxygenase inhibitor indomethacin and by trolox
(an antioxidant), suggesting that the action of TNF-α is mediated by
cyclooxygenase products and/or intracellular oxidant activity.21,22
Other than the effect of TNF-α, different explanations for the
decrease in contractility should be considered. One such possibility is an
TABLE 2 CSA, P0, and SF for IIM cases and female controls
Median (IQR) Mean ± SD
Contractility parameter IIMs Controls IIMs Controls P value
CSA (μm2)
All fiber types combined 3847 (2462–5806) 3317 (2826–4299) 4366 ± 2337 3657 ± 1309 .144
Type I fibers 2733 (2205–4299) 3317 (2826–4299) 3342 ± 1787 3656 ± 1268 .028
Type IIA fibers 4534 (2641–6325) 3317 (2826–4128) 4796 ± 2462 3623 ± 1423 .047
P0 (mN)
All fiber types combined 0.28 (0.18–0.43) 0.37 (0.29–0.46) 0.33 ± 0.18 0.39 ± 0.15 <.0001
Type I fibers 0.19 (0.14–0.26) 0.33 (0.26–0.45) 0.21 ± 0.09 0.36 ± 0.13 <.0001
Type IIA fibers 0.37 (0.22–0.47) 0.41 (0.33–0.52) 0.37 ± 0.16 0.44 ± 0.18 .047
SF (kN/m2)
All fiber types combined 73 (54–98) 108 (81–136) 81 ± 37 115 ± 48 <.0001
Type I fibers 63 (46–94) 104 (79–131) 73 ± 36 105 ± 38 <.0001
Type IIA fibers 77 (61–104) 121 (101–146) 85 ± 35 131 ± 48 <.0001
Abbreviations: CSA, cross-sectional area; IIM, inflammatory myopathy; IQR, interquartile range; P0, maximum force; SF, specific force.
F IGURE 1 Maximum force (A) and specific force (B) of type I and IIA fibers from controls and idiopathic inflammatory myopathy cases.
P0, maximum force; SF, specific force
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indirect effect of the disease process on force production, mediated by
muscle disuse and inactivity. The effects of both long- and short-term
immobilization have been investigated, and have been shown to
decrease single-fiber force production in some,23–25 but not all, studies.26
However, it should be noted that the extent of immobilization in these
studies was substantial (complete immobilization, bed rest, or chronic spi-
nal cord injury), whereas all participants in the current study were still
mobile, although they had limited mobility from weakness and fatigue.
Our study has potential limitations. First, the number of partici-
pants was small, and the findings should be regarded as preliminary as
the included participants may not be representative. Second, it could
be argued that the different disease entities included in the IIMs
group may have different pathological mechanisms. Although this may
be correct, they also share a number of characteristics, some of which
are likely to be relevant to the context of the current study and pro-
vide sufficient justification for grouping these entities for the purpose
of this investigation. Another limitation is the fact that quadriceps
strength was not tested in controls, but was only assumed to be
normal. Last, due to a paucity of controls, we were not able to fully
match for age. However, this is unlikely to have influenced the results,
as SF does not appear to be affected by age.27
In conclusion, the results of this exploratory study suggest that
force production of muscle fibers from patients with IIM are adversely
affected by the disease process, and this could, at least partially, explain
the weakness in these disorders. Further studies are required to eluci-
date the pathological mechanism responsible for the development of
impaired contractility. In particular, the role of the pro-inflammatory
cytokine TNF-α warrants further investigation in view of experimental
animal data. Furthermore, studies with sufficient numbers of partici-
pants are required to determine contractility in each IIM subgroup.
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